Vandenbussche, Nicolas
Pisarek, Karolina
Paemeleire, Koen
Article History
Received: 2 February 2023
Accepted: 10 June 2023
First Online: 22 June 2023
Declarations
:
: No ethics approval was required for this systematic review.
: Not applicable.
: NV has received travel grants and consulting fees from Novartis AG, TEVA Pharmaceuticals Industries Ltd., AbbVie/Allergan and Pfizer Inc.KPi declares no competing interests.KP has received personal compensation from AbbVie/Allergan, Amgen/Novartis AG, Eli Lilly and Company, Lundbeck, Teva Pharmaceuticals Industries Ltd., and Man&Science for consulting, serving on a scientific advisory board, and/or speaking and is/was a clinical trial investigator for Almirall (almotriptan), Amgen/Novartis AG (erenumab), Eli Lilly and Company (galcanezumab, lasmiditan), Lundbeck (eptinezumab) and Autonomic Technologies Inc. (sphenopalatine ganglion stimulation).